Proto Labs Inc (PRLB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Proto Labs Inc stock $52.75, price $65.69, that is 19.7% below the price, quality 72 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $22.09 – $98.68 · fair‑value band $40.69 – $65.83 · the $65.69 price screens above the $52.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Proto Labs in your weekly email
Every Wednesday you see whether Proto Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Proto Labs, Inc., together with its subsidiaries, operates as a digital manufacturer of custom parts in the United States and Europe. It offers manufacturing services, such as molding, computer numerical control machining, 3D printing, and sheet metal to developers, engineers, and supply chain teams.
Show moreShow less
The company was incorporated in 1999 and is headquartered in Maple Plain, Minnesota.
Stock analysis
Proto Labs Inc (PRLB) currently trades at $65.69, while our model-based Fair Value estimate is $52.75, 20% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $31.23 per share, and 1 of the 24 models we run sit above the $65.69 price.
Bear case: the Asset-Based group reads lowest at $6.03, and 23 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $40.69 (bear) to $65.83 (bull), the price of $65.69 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Proto Labs Inc reported revenue of $533M in FY2025 versus $488M in FY2021, a compound +2.2%/yr. Reported net income was $21.2M in FY2025, compounding −10.7%/yr from FY2021.
Key figures
Market cap $1.6B Small · P/E ratio 52.1 · P/S ratio 2.76 · EPS (TTM) $1.26 · Net margin 6.0% · Return on equity 5.1% · Return on assets (EBIT) 3.4% (5-year average) · Operating margin 9.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −38% fair-value upside, at −20%, PRLB screens cheaper than that median.
Fair Value models
Bear$40.69Fair Value $52.75Bull$65.83
Price $65.69 · Downside -19.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.08 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$26.78$37.31$51.3681
Growth DCF$26.65$36.20$48.2779
Owner Earnings$19.79$27.00$36.6177
All 24 models by family
DCF Models
FCF DCF$26.78$37.31$51.3681
Owner Earnings$19.79$27.00$36.6177
5Y Revenue Exit$19.46$25.99$34.1074
5Y EBITDA Exit$26.59$39.86$55.5975
5Y P/E Exit$21.17$29.32$37.9472
10Y Revenue Exit$22.12$28.53$36.9368
10Y EBITDA Exit$26.35$37.02$51.5969
10Y P/E Exit$23.32$30.57$39.5565
Earnings-Based
Graham-Dodd$6.05$22.59$30.5464
Lynch FV$5.44$7.77$10.1061
PEG = 1.0$5.44$7.77$10.1057
EPV$9.62$10.22$10.7274
Multiples
P/E Multiple$14.01$18.69$23.3663
P/S Multiple$11.34$15.13$18.9158
P/B Multiple$54.71$72.95$91.1955
EV/EBIT$18.44$23.11$27.7766
EV/EBITDA$28.96$37.13$45.3067
EV/Revenue$14.44$18.72$23.0054
Asset-Based
NCAV (Graham)$3.98$6.03$7.5454
Growth DCF
Growth DCF$26.65$36.20$48.2779
Rev-Margin DCF$19.46$26.25$34.5674
Economic Profit
Residual Income$17.03$17.28$18.4771
ROIC Compounder$9.62$10.22$10.7272
Growth Earnings
Growth-Adj P/E$10.06$14.37$18.6867
The fair value above starts from this blend and is adjusted for a cyclical trough year.
In the last 6 months, 2 officers or directors bought shares worth $101,230, most recently on Nov 3, 2026. Over the same period, 3 people sold shares worth $2.7M. Buying cluster
BuyRainer GawlickDirector720 shares at $68.18$49,090Nov 3, 2026
BuySuresh KrishnaPresident and CEO, Director750 shares at $69.52$52,140Nov 2, 2026
SaleDaniel SchumacherChief Financial Officer2× since Sep 16, 2026: 10,000 shares, avg. $90.26$902,629Sep 24, 202610b5-1 plan
SaleSven WehrweinDirector2,000 shares at $77.28$154,555Jun 2, 2026
SaleMichael R. KenisonChief Operations Officer5× since Nov 25, 2025: 34,211 shares, avg. $66.80$2.3MMay 12, 202610b5-1 plan
Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Start year 2020 (pandemic). Over 10 years: +7.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.3% vs −5.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.1% a year for the price and +4.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Metal Fabrication · 260 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−19.7% · Above median
Profitability
Return on equity (12 months)5.1% · Below median
Return on assets2.8% · Above median
Net margin (12 months)6.0% · Above median
Operating margin (12 months)9.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)14.0% · Above median
Valuation Multiplesvs Metal Fabrication median · lower = cheaper
P/E (12 months)52.1× · Priciest 25%
P/B2.39× · Pricier than median
P/S (12 months)2.76× · Pricier than median
Price / free cash flow (fiscal year)26.8× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Proto Labs Inc (PRLB) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $52.75 versus a price of $65.69, about 20% lower (overvalued).
What is the fair value of PRLB?
Our model-based fair value for Proto Labs Inc is $52.75 (as of Nov 7, 2026), built from audited fundamentals. The current price: $65.69.
What is the quality score of PRLB?
Proto Labs Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Proto Labs Inc (PRLB)?
Our model-based price target is the fair value of $52.75 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario $40.69, optimistic scenario $65.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Proto Labs Inc stock forecast for 2026?
Our models put fair value at $52.75, about 20% lower versus a price of $65.69 (overvalued). Cautious scenario $40.69, optimistic scenario $65.83. The calculation is refreshed regularly with new filings.
What is the revenue of Proto Labs Inc (PRLB)?
Proto Labs Inc reported trailing-twelve-month revenue of about $579M (latest available figure, as of Nov 7, 2026).
What growth is priced into Proto Labs Inc (PRLB)?
For today's price to be fair in a discounted-cash-flow model, Proto Labs Inc would have to grow free cash flow by +19.9 % per year for five years (discount rate 12.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of PRLB use?
Our models discount Proto Labs Inc at 12.3 %: a base by market capitalisation (small), damped by beta 1.38, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Proto Labs Inc that is +19.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.3 %) and the same formula as our fair value.
How much growth has Proto Labs Inc (PRLB) delivered so far?
Over the past 5 years revenue at Proto Labs Inc grew +4.2 % a year. The price currently implies free-cash-flow growth of +19.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Proto Labs Inc (PRLB) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Proto Labs Inc (+19.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Proto Labs Inc (PRLB)?
The free-cash-flow yield on the price is 3.73 %: that much free cash flow Proto Labs Inc produces per unit of market value. When it exceeds the discount rate of our models (12.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Proto Labs Inc (PRLB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Proto Labs Inc it is $52.75 per share (as of Nov 7, 2026), against a price of $65.69. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Proto Labs Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, PRLB trades above its calculated fair value: price $65.69, fair value $52.75, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRLB?
No. The price is what the market pays today ($65.69); the fair value is what the company's own numbers justify ($52.75). For Proto Labs Inc the two are $12.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Proto Labs Inc worth?
The market values Proto Labs Inc at about $1.6B (market capitalisation, as of Nov 7, 2026). Per share that is $65.69; our models calculate a fair value of $52.75 per share.
What do the bullish and bearish scenarios say about PRLB?
Our models span a range for Proto Labs Inc: cautious scenario $40.69, base $52.75, optimistic $65.83 per share (as of Nov 7, 2026, price $65.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PRLB?
Proto Labs Inc trades at a price-to-earnings ratio of 52.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $52.75 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings, FY2024, FY2025 ex one-offs: 43.8. Other multiples: PEG 0.9, P/B 2.4, P/S 2.8, EV/EBITDA 18.7.
What is the PEG ratio of PRLB?
The PEG ratio of Proto Labs Inc is 0.86 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Proto Labs Inc (PRLB)?
Balance-sheet figures for Proto Labs Inc (as of Nov 7, 2026): return on equity 5.1%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is PRLB from its 52-week high?
Proto Labs Inc trades at $65.69, about 33% below its 52-week high of $98.68 and 40% above the low of $46.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $52.75 is for.
Which stocks are comparable to Proto Labs Inc?
From the same area (Industrials) we also value ATI Inc, Carpenter Technology Corporation, Mueller Industries, Inc, Bharat Forge Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Proto Labs Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $65.69, calculated fair value $52.75 (−20%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRLB calculated?
We run Proto Labs Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $52.75 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Proto Labs Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Proto Labs Inc (PRLB)?
The closing price on Nov 6, 2026 was $65.69. Our model-based fair value is $52.75, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Proto Labs Inc right now?
Solid but not exceptional quality (72/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Proto Labs Inc (PRLB) come from?
Earnings per share at Proto Labs Inc grew −8.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.5 %, EBIT margin −15.9 %, tax rate −0.4 %, residual (interest, one-offs) +0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Proto Labs Inc
How large is the market capitalisation of Proto Labs Inc (PRLB)?
The market capitalisation of Proto Labs Inc is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Proto Labs Inc (PRLB)?
The price-to-sales ratio of Proto Labs Inc is 2.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Proto Labs Inc (PRLB)?
Earnings per share at Proto Labs Inc are $1.26 (price ÷ EPS = P/E 52.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Proto Labs Inc (PRLB)?
The net margin of Proto Labs Inc is 6.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Proto Labs Inc (PRLB)?
The return on equity (ROE) of Proto Labs Inc is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Proto Labs Inc (PRLB)?
On an EBIT basis the return on assets of Proto Labs Inc is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Proto Labs Inc (PRLB)?
The operating margin of Proto Labs Inc is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Proto Labs Inc (PRLB)?
Revenue at Proto Labs Inc is growing +14.0% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Proto Labs Inc (PRLB)?
Earnings per share at Proto Labs Inc are growing +60.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Proto Labs Inc (PRLB) hold?
Proto Labs Inc holds more cash than debt, $106M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Proto Labs Inc in the live analysis
One click puts Proto Labs Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026